Big names, big backers: David Baker joins OrbiMed, F-Prime, Khosla and others as protein-ligand biotech launches
David Baker, one of the biggest names in the protein design space with multiple scientific prizes, his own institute at the University of Washington and a few companies to his name, is throwing his weight behind another biotech — one that seeks to take his famed work in protein folding and extend it further into drug discovery and development.
CHARM Therapeutics, based out of the UK, announced its launch bright and early Thursday morning, with $50 million in equity financing. CEO Laksh Aithani declined to give specifics on the financing runway, but he did say that, “Historically, these sorts of Series A rounds have been able to bankroll companies often to a sort of development candidate stage.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
